Ann Thorac Surg 2007;83:1705-1706
© 2007 The Society of Thoracic Surgeons
Original Articles: Cardiovascular
Invited commentary
Paul Hendry, MD
Division of Cardiothoracic Surgery, University of Ottawa Heart Institute, 40 Ruskin St, Room H3404B, Ottawa, Ontario, Canada K1Y 4W7
(Email: phendry@ottawaheart.ca).
| The first 20% of the full text of this article appears below. |
Pulmonary hypertension is common in end-stage heart failure patients who are being assessed for candidacy for cardiac transplantation. Testing with either milrinone, nitric oxide, or prostaglandins can aid in the determination of reversibility of pulmonary hypertension. The International Society of Heart Lung Transplantation guidelines and Canadian Cardiovascular Society Consensus Conference on Cardiac Transplantation suggest that pulmonary hypertension greater than 50 mm Hg systolic, pulmonary vascular resistance greater than 4 to 5 Wood units, or a transpulmonary gradient greater than 15 to 16 are relative, if not absolute contraindications to cardiac transplantation [1, 2]. Although the medical treatment of advanced heart . . . [Full Text of this Article]
Related Article
-
Medically Refractory Pulmonary Hypertension: Treatment With Nonpulsatile Left Ventricular Assist Devices
- Christian D. Etz, Henryk A. Welp, Tony D.T. Tjan, Andreas Hoffmeier, Ernst Weigang, Hans H. Scheld, and Christof Schmid
Ann. Thorac. Surg. 2007 83: 1697-1705.
[Abstract]
[Full Text]
[PDF]
Copyright © 2007 by The Society of Thoracic Surgeons.